Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial (Q80568663)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

main subject

lymphoblastic leukemia

1 reference

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

E Tavernier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J-M Boiron

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

F Huguet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

K Bradstock

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

N Vey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

T Kovacsovics

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A Delannoy

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

N Fegueux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

P Fenaux

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A Stamatoullas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

O Tournilhac

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A Buzyn

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

O Reman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C Charrin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J Gabert

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

V Lhéritier

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J-P Vernant

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

H Dombret

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

X Thomas

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

GET-LALA Group

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Swiss Group for Clinical Cancer Research SAKK

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Australasian Leukaemia and Lymphoma Group

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

5 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1907-1914

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17611565%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404824

1 January 2020

exact match

0 references

cites work

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Acute lymphoblastic leukemia--progress in children, less in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

L-asparaginase and PEG asparaginase--past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Chemotherapy versus transplantation in acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Outcomes among 562 recipients of placental-blood transplants from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021

Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404824

7 January 2021